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ABSTRACT
Objective: To assess whether estimates of the effectiveness
of inﬂuenza vaccination in reducing rates of hospitalizations
and all-cause mortality derived from cross-sectional data
could be improved by applying the instrumental variable (IV)
method to data representing the community-dwelling elderly
population in the United States in order to adjust for self-
selection bias.
Methods: Secondary data analysis, using the 1996–97
Medicare Current Beneﬁciary Survey data. First, using single-
equation probit regressions this study analyzed inﬂuenza-
related hospitalization and death due to all causes predicted
by vaccination status, which was measured by claims or sur-
vey data. Second, to adjust for potential self-selection of the
vaccine receipt, for example, higher vaccination rates among
high-risk individuals, bivariate probit (BVP) models and two-
stage least squares (2SLS) models were employed. The IV
was having either arthritis or gout.
Results: In single-equation probit models, vaccination
appeared to be ineffective or even to increase the probability
of adverse outcomes. Based on BVP and 2SLS models, vac-
cination was demonstrated to be effective in reducing inﬂu-
enza-related hospitalization by at least 31%. The BVP model
results implied signiﬁcant self-selection in the single-equation
probit models.
Conclusions: Adjusting for self-selection, BVP analyses
yielded vaccine effectiveness estimates for a nationally
representative cross-sectional sample of the community-
dwelling elderly population that are consistent with pre-
vious estimates based on randomized controlled trials,
prospective cohort studies, and meta-analyses. This result
suggests that analyses with 2SLS and BVP in particular may
be useful for the analysis of observational data regarding
prevention in which self-selection is an important potential
source of bias.
Keywords: bivariate probit model, inﬂuenza vaccination,
instrumental variable method, self-selection bias, vaccine
effectiveness.
Introduction
Inﬂuenza and pneumonia ranked ﬁfth among all
causes of death for those aged 65 and older and ranked
sixth among all age groups in the United States in 1997
[1]. Medicare reimbursement for excess hospitaliza-
tion ranged from $750 million to $1 billion per epi-
demic from 1989 to 1991 [2]. At present, the main
option for reducing the considerable impact of inﬂu-
enza in the United States is annual vaccination before
the inﬂuenza season for people at high-risk for inﬂu-
enza and its complications and health-care workers
[3]. People at high-risk include all those 50 years and
older, residents of nursing homes and other chronic
care facilities, and nonelderly individuals with speciﬁc
chronic medical conditions, for example, chronic dis-
orders of the pulmonary or cardiovascular systems,
including asthma [3].
To the best of our knowledge, only two randomized
clinical trials (RCTs) have been conducted to examine
the efﬁcacy of inﬂuenza vaccination in community eld-
erly population in the Netherlands and Great Britain
[4,5]. Over time, RCTs have become more difﬁcult to
conduct for some treatments because of ethical, ﬁnan-
cial, and administrative difﬁculties, particularly for
studies that are large in scale, with frequent observa-
tions, and with a longer follow-up period. When
observational studies are the only choice available,
particularly for effectiveness rather than efﬁcacy
research, the analysis of observational data may yield a
biased effectiveness estimate for interventions that can
be chosen by individuals. The choice leads to a poten-
tial violation of an assumption for unbiased estimated,
that is, that the residual term in a model is not corre-
lated with an explanatory variable. The correlation
that leads to violations of the assumption, an endog-
eneity problem, may stem from two problems: the
omitted variable problem and the simultaneous cau-
sality problem, that is, two-way causality between an
outcome and an intervention. The “omitted variable
problem” can, in theory, be solved by an observational
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data analysis including all variables possibly correlated
with the intervention. This solution is still unable to
solve the latter “simultaneous causality problem” with
observational data.
The instrumental variable (IV) method, an econo-
metric technique, can address both problems in evalu-
ating intervention effectiveness using an observational
data with a limited number of variables. Although this
technique has been applied in evaluating various types
of acute care such as acute myocardial infarction [6]
and surgical treatments for breast cancer [7], this tech-
nique could make further contributions to the litera-
ture of preventive care effectiveness evaluation.
As McClellan and Newhouse stated, the IV method
should be used as a complement rather than a substi-
tute for a randomized controlled experiment [8]. Nev-
ertheless, when RCT data are limited, IV approaches
are useful but will help to control an endogeneity
problem only if good IVs are identiﬁed in evaluating a
medical intervention for which the choice is affected by
unobservable factors. The IV method’s key advantage
compared with other statistical methods used to
analyze observational data is the ability to isolate
exogenous effects of an intervention by excluding
endogenous self-selection effects without having to
directly measure such self-selection. Because of this
advantage the IV method has the potential to be supe-
rior to a conventional single-equation model unless all
variables possibly correlated to the focused interven-
tion are available for a single-equation model, that is,
no omitted variable problem.
Even if an intervention is truly effective in reducing
the risk of adverse health outcomes, a single-equation
model  could  mistakenly  lead  to  the  inference  that
the intervention is either ineffective or signiﬁcantly
“increases” the adverse outcome risks when high-risk
individuals are more likely to receive the intervention.
When the opposite type of self-selection occurs, inter-
vention effectiveness could be overestimated to the
extent that low-risk individuals are more likely to
receive the intervention. Because a more intensive
medical intervention tends to be offered to higher-risk
individuals, its effectiveness is likely to be underesti-
mated when using observational data due to the
former type of self-selection as observed in the litera-
ture, for example, intensive treatment of acute myo-
cardial infarction [6], and more and early prenatal
care for women with a higher risk of bearing a low
birth weight child [9].
The two-stage estimation method, a subtype of the
IV method, is a general way to obtain consistent
estimates by adjusting for a potential endogeneity
problem, for example, self-selection [10]. Under the
two-stage estimation method, the ﬁrst-stage equation
regresses a potentially self-selected variable on covari-
ates. This stage aims at obtaining predicted values of
the self-selected variable, that is, the ﬂu shot (FS)
receipt. The second-stage equation regresses a health
outcome variable on covariates including the predicted
values of the self-selected variable obtained from the
ﬁrst-stage regression in place of the self-selected vari-
able [10].
Special caution is needed in choosing an appropri-
ate subtype of the IV method depending on the types of
outcome and intervention. In particular, the appropri-
ate estimation method depends on whether variables
are continuous or dichotomous. This is because the
two-stage estimation method does not generally yield
an unbiased effectiveness estimate, resulting from the
second-stage probit regression maximizing a mis-
speciﬁed likelihood, when both an outcome variable
and an endogenous intervention variable are dichoto-
mous [10,11]. One solution is a bivariate probit (BVP)
model. Another solution is to use a two-stage least
squares (2SLS) model that treats these dichotomous
dependent variables and an endogenous covariate as
continuous variables and runs ordinary least squares
(OLS) models, instead of probit models, for the ﬁrst
and the second-stages to obtain consistent estimates
[11].
In general, BVP models have received relatively less
attention in the clinical effectiveness evaluation litera-
ture, but have been used by studies focusing on the
association between health condition and employment
[12] and that between health insurance choice and
health-care utilization [13].
The purpose of our article is to illustrate in detail
how to evaluate medical intervention effectiveness
with observational data, adjusting for self-selection of
the intervention by the IV method when both an inter-
vention and outcome measures are dichotomous.
Among subtypes of the IV methods, we employed BVP
and 2SLS analyses as our main models that can be eas-
ily implemented by statistical software such as STATA
Version 7 or later [14]. As a potentially endogenous
intervention example, inﬂuenza vaccination (ﬂu shot,
FS) among Medicare elderly population was used for
two reasons. One is the substantial impact of inﬂuenza
epidemics as illustrated above. The second is that
ﬁndings from our IV method analyses with nationally
representative data are expected to yield signiﬁcant
contributions to the inﬂuenza vaccination literature in
terms of improving generalizability, compared with
past RCT analyses. To the best of our knowledge, our
study is the ﬁrst to evaluate the effectiveness of any
type of vaccination adjusting for self-selection by the
IV method.
Concretely, we test two major hypotheses concern-
ing inﬂuenza vaccination effectiveness estimated by
BVP and 2SLS models:
Hypothesis 1
A single-equation probit model will underestimate the
vaccine effectiveness in terms of magnitude and statis-
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tical signiﬁcance level compared with BVP and 2SLS
models adjusting for self-selection of inﬂuenza vacci-
nation. This is because individuals at higher risk are
more likely to receive shots among the US Medicare
elderly population. According to self-report in Medi-
care Current Beneﬁciary Survey (MCBS) data, the FS
rate has steadily increased from 1991–92 season
(49%) to 1999–2000 season (68%) [15]. FS rate for
1996–97 seasons for the entire Medicare elderly pop-
ulation was 62% in our data set.
Hypothesis 2
The qualitative differences in FS effectiveness estimates
in hypothesis 1, depending on the adjustment for self-
selection, are robust to sensitivity analyses in varying
outcome periods, the scope of outcomes, and sources
of data on FS receipt, that is, either claims data or
survey data. In addition, the results of the sensitivity
analyses in hypothesis 2 will be predictable. FS
effectiveness estimates will be greater in magnitude
when using a shorter outcome period and when using
survey data. Flu epidemic was reported to occur for
different periods and at different severity levels
depending on a state, from October to March [16].
Because a larger number of states experienced ﬂu epi-
demic during a shorter outcome period, FS effective-
ness will be greater in magnitude using a shorter period
than a longer period. Because some FSs received out-
side Medicare billing system were not included in
claims data, FS effectiveness will be underestimated
with claims data.
Data and Methods
MCBS Data and Study Population
The MCBS is a longitudinal survey conducted by the
Centers for Medicare and Medicaid Services [17]. This
study used MCBS Cost and Use data in calendar years
1996 and 1997, focusing on the inﬂuenza season start-
ing in fall 1996 and ending in spring 1997. The study
population was deﬁned to be individuals aged 65 years
or older whom were continuously covered by Medi-
care Part B from September 1, 1996 to March 31,
1997, including those who were alive on September 1,
1996 but died during the study time period. Medicare
Health Maintenance Organization (HMO) enrollees
were not included because Medicare claims with the
exact dates of FSs were not available for Medicare
HMO enrollees [17]. Furthermore, this study used
only the community population following most of past
literature, where FS effectiveness is explored in either
the community population or the facility population
because of the differences in individual characteristics,
particularly health conditions [18,19]. To yield results
generalizable for the entire Medicare population with
the observed number of the study subjects (n = 4338),
two sample structure variables were used: a cluster
identiﬁer variable and a sampling probability weight
variable.
Dependent Variables and Major Explanatory Variable
Variables used in these analyses are deﬁned and sum-
marized in Table 1. Medicare inpatient claims data on
primary diagnosis and admission diagnosis between
October 1, 1996, and March 31, 1997, were used to
identify hospitalizations resulting from inﬂuenza-
related diseases, because Centers for Disease Control
and Prevention (CDC) reported that the inﬂuenza sea-
son lasted from October 1996 to March 1997 in most
states [17]. To account for the inﬂuenza season varying
across geographic regions, we examined three addi-
tional outcome periods, starting November 1, Decem-
ber 1 and January 1.
On the basis of previous literature this study uses
two deﬁnitions concerning the diagnoses of inﬂuenza
and its complications [2,20–22]. The narrow deﬁni-
tion included pneumonia and inﬂuenza (ICD-9-CM
codes 480–487) only. The broader deﬁnition addition-
ally included acute bronchitis (ICD-9-CM code 466).
Table 1 Variable deﬁnitions and sample means (n = 4338)
Variable deﬁnition Mean (SD)
Dependent variable
Hospitalization due to pneumonia and inﬂuenza
10/01/1996–3/31/1997 0.0145
11/01/1996–3/31/1997 0.0131
12/01/1996–3/31/1997 0.0120
1/01/1997–3/31/1997 0.0085
Hospitalization due to pneumonia and inﬂuenza, 
or acute bronchitis
10/01/1996–3/31/1997 0.0159
11/01/1996–3/31/1997 0.0145
12/01/1996–3/31/1997 0.0131
1/01/1997–3/31/1997 0.0095
Death due to all causes
10/01/1996–3/31/1997 0.0106
11/01/1996–3/31/1997 0.0106
12/01/1996–3/31/1997 0.0106
1/01/1997–3/31/1997 0.0106
Explanatory variables
Flu shot (FS) received: 9/1/1996–3/31/1997 based 
on claims data (d.v.)
0.502
Flu shot (FS) received: 9/1/1996–3/31/1997 based 
on survey data (d.v.)
0.688
Chronic condition: high level (d.v.) 0.199
Chronic condition: low level (d.v.) 0.726
Ever receiving pneumococcal vaccination (d.v.) 0.475
Ever smoked (d.v.) 0.560
Age (years) 77.21 (7.10)
Male (d.v.) 0.405
Race: nonwhite (d.v.) 0.150
Education: 13 years or more (d.v.) 0.264
Medigap supplemental insurance (d.v.) 0.752
Household member: 2 or more (d.v.) 0.646
Residence in metropolitan area (d.v.) 0.663
9 census region (d.v.): New England/E.N. central/ 0.0327/0.183/
W.N. Central/South Atlantic/ 0.0768/0.213/
E.S. Central/W.E. Central/ 0.0620/0.106/
Mountain/Paciﬁc 0.0549/0.0906
Instrumental variables (IV)
Arthritis (secondary diagnosis) or gout (d.v.) 0.0763
d.v., dichotomous variable.
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MCBS survey data were used to identify cases of death
from all causes that occurred between October 1, 1996
and March 31, 1997, because claims data do not
include all death cases.
FS variables were created from either claims data or
survey data. Based on the claims data, 50.2% of the
study population received FSs, from September 1,
1996 to March 31, 1997 (Table 1). Survey data indi-
cated that 68.8% received an FS during 1996–97
seasons.
Nichol and colleagues deﬁne three levels of inﬂu-
enza risk depending on chronic conditions: high-risk
(those with heart or lung disease), intermediate-risk
(those with diabetes, renal disease, rheumatologic dis-
ease or dementia and/or stroke but not underlying
heart or lung disease), and low-risk (those without any
of these diseases or conditions) [21]. We created indi-
cator variables associated with these three levels. In
addition to these indicators of chronic condition levels
that were expected to reﬂect actual inﬂuenza risk more
systematically than a list of speciﬁc diseases, ever
smoking status and age were included in analyses and
expected to be associated with a higher likelihood of
adverse inﬂuenza-related outcomes.
Analytical Methods
As a preliminary analysis, a single-equation probit
model was used to estimate associations between the
inﬂuenza-related adverse health outcomes (e.g., inﬂu-
enza-related hospitalization and death due to all
causes) and the receipt of an FS.
Our main analyses adopted BVP and 2SLS models.
The fundamental goal shared by 2SLS and BVP is the
same as using an additional exogenous “instrumen-
tal” variable to isolate a part of a treatment variable
that is uncorrelated with the error term. A BVP model
provides not only consistent but also efﬁcient esti-
mates, being dependent on the assumptions of the
joint distribution of error terms for the dependent var-
iable and the endogenous covariate [11]. In contrast,
2SLS models are robust to this assumption of bivariate
normal distribution. One of our major interests, meas-
uring the magnitude of the FS effectiveness, is
expected to be more precisely estimated by BVP mod-
els than 2SLS models. The BVP model estimates Equa-
tions 1 and 2 simultaneously, treating both FS and
outcome in these two equations as dichotomous
[11,23]. IV1 represents an IV unique to Equation 1,
and, in Equations 1 and 2, X1 and X2 are other exog-
enous controlling covariates. Our IV, having either
arthritis as a secondary diagnosis or gout, was chronic
diseases that require a regular clinic visit, at which an
FS could be suggested and given, but are uncorrelated
with inﬂuenza risk [21,24].
First-stage equation:
y1* = α0 + α1 (IV1) + α2(X1) + ε1 (1)
y1 = 1 (received FS) if y1* > 0
y1 = 0 (not received FS) otherwise
Second-stage equation:
y2* = β0 + β1 (FS) + β2 (X1) + β3 (X2) + ε2 (2)
y2 = 1 (Hospitalized) if y2* > 0
y2 = 0 (Not Hospitalized) otherwise
ε1 in Equation 1, ε2 in Equation 2 ∼ Bivariate Normal 
(0, 0, 1, 1, ρ)
Following the expression by McClellan and colleagues
[6], a BVP/2SLS estimator measures the ratio (hospi-
talization rate among those with arthritis −
 hospitalization rate among those without arthritis)/
(vaccination rate among those with arthritis −
 vaccination rate among those without arthritis) in
“marginal” individuals. This ratio indicates the incre-
mental or marginal effect of vaccination over the
change in likelihood in vaccination across two groups,
those with and without arthritis. In case of an RCT
estimator, this ratio’s denominator is equal to one, that
is, vaccination status between a treatment group and a
control group. The vaccination effects based on BVP/
2SLS estimators are applicable for “marginal” individ-
uals for whom arthritis is an important factor in the
vaccination decision.
Instrumental Variable Assumptions
Our IV passed the two applicable assumption tests for
valid IVs as below. First, IVs should be correlated with
an endogenous variable [10]. Concretely, in a ﬁrst-
stage Equation 1 where the FS receipt is an outcome
variable, a standard t-test indicated that an IV’s coef-
ﬁcient, for example, α1, was signiﬁcant at the 5% level
after controlling for other exogenous covariates when
arthritis and gout were combined to one variable. That
is, when these two conditions are included as two sep-
arate IVs, the assumption that these two IVs are jointly
signiﬁcant was rejected. Second, IVs should also have
enough “explanatory power” for an endogenous var-
iable after controlling for other exogenous covariates
in the ﬁrst-stage Equation 1. Explanatory power is
tested by an F-statistic measuring the increase in R-
squared, when an IV is incrementally added as an
explanatory variable, in case of a linear model.
Because there is no comparable test in limited depend-
ent variable models, we tested this assumption by
mimicking the linear model by using pseudo-R-
squared. Standard F-test using pseudo-R-squared indi-
cated signiﬁcant explanatory power at the 5% level
when arthritis and gout were combined to one varia-
ble, not included as two separate IVs, in BVP analyses.
For 2SLS analyses, the combined IV did not pass these
relevancy tests. A general disadvantage of the IV
method is the difﬁculty in ﬁnding a unique set of IVs
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for each endogenous variable. To use a less appropri-
ate IV, for example, weakly correlated with an endog-
enous variable, could yield biased estimates [25].
Although applicable but not testable in our case, the
third assumption for valid IVs is that IVs should be
uncorrelated with the error term in the second-stage
Equation 2 where a health outcome is a dependent var-
iable. This exogeneity assumption cannot be directly
tested when a model is exactly identiﬁed, that is, the
number of IVs is equal to that of endogenous variables,
as in our models.
All statistical analyses were performed using statis-
tical software STATA Version 7 [14].
Results
The estimates of vaccine effectiveness were summa-
rized in Table 2: those estimated by single-equation
probit models (columns 1 and 2) and by BVP models
(columns 3 and 4) where FS was measured by claims
data (columns 1 and 3) and survey data (columns 2
and 4). These vaccine estimates were imputed based on
the marginal effects of the probit models exploring
associations between the inﬂuenza-related adverse
health outcomes and the receipt of FS summarized in
Table 3. In Table 3, column 1 presents the marginal
effects estimated by single-equation probit models.
Columns 2 and 3 indicate the marginal effects esti-
mated by a BVP model and a correlation coefﬁcient in
a BVP model, respectively.
The imputation of FS effectiveness based on the FS
marginal effects was exempliﬁed as follows. The ﬁrst
row and second column in Table 3 shows that the FS’s
marginal effect was 0.69% when outcome is hospital-
ization due to pneumonia and inﬂuenza and estimated
by a BVP model. Because the observed probability of
hospitalization among the unvaccinated individuals
was 1.62%, FS was approximately 43% effective,
marginal effect (0.69) divided by the hospitalization
rate among the unvaccinated (1.62), in preventing hos-
pitalization due to pneumonia and inﬂuenza between
October and March.
All estimates controlled for three levels of chronic
diseases detailed in the methods section, ever receiving
the pneumococcal vaccination, ever smoking status,
age, sex, race, educational attainment, presence of sup-
plemental health insurance, the number in the house-
hold, metropolitan area, and nine census regions.
Hypothesis 1, the single-equation model underesti-
mates FS effectiveness, was strongly supported by our
empirical results. For instance, when an individual
receives an FS, the individuals’ probability of hospital-
ization from December to March due to the narrow
deﬁnition of inﬂuenza-related diagnoses decreased by
41% compared with those who missed an FS at a sta-
tistically signiﬁcant level (P < 0.01) in a BVP model. In
a single-equation probit model, FS effectiveness was
2%, which was statistically not different from zero
(Table 2, row 3, columns 2 and 4).
The estimates of improved FS effectiveness, hypoth-
esis 2, were partly supported by our empirical sensi-
tivity analyses. Such improvement in estimates was
robust to the changes in outcome periods, sources of
data on FS receipt, and relatively robust to the scope of
outcomes (Table 2). FS effectiveness tended to be
greater in magnitude and statistical signiﬁcance level
when the outcome scope was deﬁned more narrowly.
Such obvious trend was not observed in sensitivity
Table 2 Effectiveness of inﬂuenza vaccination adjusting for self-selection of vaccination (n = 4338)
Outcome Period
Single-equation 
probit model (%)
Bivariate probit model 
(adjusting for self-selection
of vaccination) (%) 
Claims data* Survey data* Claims data* Survey data*
Hospitalization
due to pneumonia
and inﬂuenza
(P & I)
10/01/1996–3/31/1997
11/01/1996–3/31/1997
12/01/1996–3/31/1997
1/01/1997–3/31/1997
14.44
17.09†
16.41¶
1.27
−17.56†,‡
−6.58‡
1.76
−4.25‡
42.69§
65.43§
46.98§
30.83
16.83
52.70†
40.59§
483.15§
Hospitalization 10/01/1996–3/31/1997 9.60 −17.86†,‡ 31.26§ −21.43‡,§
due to P & I, or 11/01/1996–3/31/1997 11.98 −7.96‡ 44.85§ 1.66
acute bronchitis 12/01/1996–3/31/1997 12.84 0.30 34.79§ 3.03
1/01/1997–3/31/1997 −6.35‡ −3.57‡ 11.83 9.36
Death due to all 10/01/1996–3/31/1997 −19.56‡ −11.26‡ 10.18 46.40
causes 11/01/1996–3/31/1997 −19.56‡ −11.26‡ 10.18 46.40
12/01/1996–3/31/1997 −19.56‡ −11.26‡ 10.18 46.40
1/01/1997–3/31/1997 −19.56‡ −11.26‡ 10.18 46.40
*Data source of vaccination status.
†Signiﬁcant at 5%.
‡Negative values indicate the increased risk of outcome.
§Signiﬁcant at 1% (based on t-static in Table 3).
¶Signiﬁcant at 10%.
All models controlled for age, age-squared, sex, race, education, supplemental insurance, number of household, metropolitan residence, ever smoking, ever receiving pneu-
mococcal vaccination, nine census regions and three levels of chronic conditions relating to ﬂu risks (heart disease, lung disease, diabetes, renal disease, rheumatologic disease,
dementia and stroke).
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analyses changing the sources of data on FS receipt
and outcome periods.
Self-selection of FS due to unobservable factors sug-
gesting high risk was implied by the estimated corre-
lation coefﬁcient (ρ) and the explanatory variables
estimates in BVP models. That is, the estimated ρ was
positive and statistically signiﬁcant (P < 0.05) in most
models presented in column 3 (Table 3). Both BVP
models and 2SLS models (not presented in Tables)
changed signs, magnitudes, and efﬁciency of some esti-
mates, particularly FSs compared with single-equation
probit models (Table 3). FS estimates in 2SLS models
were statistically signiﬁcant only when an outcome is
hospitalization due to pneumonia and inﬂuenza from
January to March, and implausibly large in magni-
tude, being greater than 200%.
Discussion
Although high-risk individuals could be either more or
less likely to self-select a medically based intervention,
only the former type of self-selection was apparent in
all of our analyses and hence the FS marginal effect
estimates were biased in the direction of less effective-
ness. When the BVP and 2SLS models adjust for the
potential endogeneity problem due to self-selected FSs,
the marginal effects of FSs changed to the expected
direction, being negative in all models (Table 3, col-
umns 2 and 3). FS effectiveness, based on these nega-
tive marginal effects, was statistically signiﬁcant in
most BVP models with hospitalization due to pneu-
monia and inﬂuenza, and some 2SLS models with a
narrowly deﬁned adverse health outcome. These sig-
niﬁcant FS effectiveness estimates in BVP and 2SLS
models were consistent with the CDC’s report that
delivered FSs contained a good antigen match
throughout the 1996–97 inﬂuenza season nation-wide
[16].
Possible unobservable factors motivating FS self-
selection are preference for FS and unmeasured health
status. These possible unobservable factors were
implied by other empirical results. Namely, individuals
with FSs were more likely to have a past season’s FS
and an inﬂuenza-related chronic condition than those
who missed FSs at a statistically signiﬁcant level
(P < 0.001).
The major purpose of conducting sensitivity analy-
ses in our study was to test the robustness of self-
selection bias in terms of its direction and statistical
signiﬁcance,  not  to  make  a  strict  comparison  with
past studies by setting a common outcome. This was
because it was difﬁcult to make other factors compa-
rable to past studies, such as the differences in study
population characteristics, unmeasured heterogeneity
between the vaccinated and the unvaccinated, degrees
of vaccine-antigen match, and laboratory conﬁrmation
of inﬂuenza.
Regarding the magnitude of FS effectiveness among
the community-dwelling elderly, previous RCTs
reported that FS was effective in reducing clinical inﬂu-
enza by 47–58% and all-cause mortality by 14% [4,5].
In a meta-analysis, FS effectiveness was 33% for
hospitalization due to pneumonia and inﬂuenza, and
50% for mortality due to all causes [26]. Large cohort
Table 3 Marginal effects of inﬂuenza vaccination adjusting for self-selection of vaccination (n = 4338)
Outcome Period
Single-equation
probit model
Bivariate probit model (adjusting
for self-selection of vaccination) 
Marginal effect
of vaccination
Marginal effect
of vaccination
Correlation
coefﬁcient
Vaccination status based on claims data
Hospitalization due 
to pneumonia and 
inﬂuenza (P & I)
10/01/96–3/31/97
11/01/96–3/31/97
12/01/96–3/31/97
−0.00234 (−1.26)
−0.00253 (−2.07)†
−0.00220 (−1.93)‡
−0.00692 (−5.75)*
−0.00968 (−70.20)*
−0.00630 (−6.59)*
0.130 (6.17)*
0.211 (4.57)*
0.157 (15.04)*
1/01/97–3/31/97 −1.12E-04 (−0.08) −0.00271 (−1.02) 0.193 (2.40)†
Hospitalization due 
to P & I or acute bronchitis
1/01/97–3/31/97
12/01/96–3/31/97
–0.00178 (−0.96)
5.58E-04 (0.31)
−0.00484 (−6.44)*
−0.00104 (−0.55)
0.113 (2.56)†
0.117 (48.01)*
Death due to all causes 1/01/97–3/31/97 0.00182 (1.41) −9.47E-04 (−0.56) 0.150 (7.86)*
Vaccination status based on survey data
Hospitalization due
to pneumonia and 
inﬂuenza (P & I)
10/01/96–3/31/97
11/01/96–3/31/97
12/01/96–3/31/97
0.00221 (2.55)†
8.29E-04 (0.94)
−2.08E-04 (−0.32)
−0.00212 (−0.65)
−0.00664 (−2.30)†
−0.00479 (−5.00)*
0.125 (2.04)†
0.202 (1.98)†
0.153 (2.69)*
1/01/97–3/31/97 3.78E-04 (0.33) −0.0430 (−10.01)* 0.759 (5.27)*
Hospitalization due to 
P & I or acute bronchitis
12/01/96–3/31/97
1/01/97–3/31/97
−3.99E-05 (−0.04)
3.68E-04 (0.25)
−4.03E-04 (−0.23)
−9.64E-04 (−1.27)
0.0137 (0.14)
0.0921 (1.56)
Death due to all causes 1/01/97–3/31/97 0.00100 (1.68) −0.00413 (−0.63) 0.226 (0.96)
*Signiﬁcant at 1%.
†Signiﬁcant at 5%.
‡Signiﬁcant at 10%.
t-static in parentheses.
Control variables are listed in Table 2.
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studies including community elderly in Europe
reported that FS effectiveness was 21–44% in reducing
hospitalization due to inﬂuenza and its related res-
piratory diseases [22,27] and 10–28% in reducing all-
cause mortality [28]. None of these cohort studies
employed IV methods, 2SLS models or BVP models, to
adjust for potential self-selection of FSs. Our FS effec-
tiveness estimates in preventing inﬂuenza-related
hospitalization were comparable in magnitude and
statistical signiﬁcance level to previously published
results. Our insigniﬁcant estimates in reducing all-
cause mortality do not contradict with an observa-
tional study using the US nationally representative
data from 1968 to 2001, reporting fewer than 10% of
all winter deaths were attributable to inﬂuenza in any
ﬂu season [29].
The FS effectiveness estimates in the literature may
have changed if they had employed BVP models to
adjust for potential self-selection of FS. For instance,
because a higher FS rate among high-risk individuals
was observed in the Swedish study like our study
[27,30], BVP models’ estimates of FS effectiveness
might have increased in the statistical signiﬁcance level
and magnitude in their study. In contrast, a low FS rate
among high-risk elderly people was reported in the
study in England and Wales [22] where FS effective-
ness magnitude might have declined after adjusting
self-selection by BVP models.
In our analyses, FS rates based on claims and survey
data were 50.2% and 68.8%, respectively. It is hard to
judge the extent of measurement error in each data
source, in part because there was no literature directly
examining the matching rates applicable to our study.
Although 10% to 20% of Medicare beneﬁciaries are
estimated to receive FSs outside the Medicare billing
system [31], close validity examinations were con-
ducted with local populations only [32,33]. Because
claims data are unable to capture the beneﬁt of FS in
reducing adverse outcomes among those actually
received FS but did not have a claims record, the
effectiveness of FS based on claims data could be
underestimated.
The adjustment of self-selection for non-HMO
enrollees would be valid and generalizable for HMO
enrollees as well, if high-risk individuals are more
likely to receive FSs among HMO enrollees. Some
studies indicated that Medicare HMO enrollees on
average are healthier [34] and more likely to get FSs
[35]. Thus, healthy individuals in HMOs are more
likely to get FSs than healthy individuals in the general
population. Our results ﬁnd that we are underestimat-
ing the effectiveness of FSs in the non-HMO popula-
tion. If we added HMO enrollees, we would have a
more balanced mixed of individuals getting FSs based
on health status. That is, the estimate including HMO
enrollees would seem to be less biased toward
ineffectiveness.
Although not presented in this article, most predic-
tors of inﬂuenza-related adverse health outcomes
conformed with the literature; an exacerbated chronic
condition level, advancement in age, and smoking his-
tory were positively associated with adverse outcomes
[21,36]. Such conformity reinforces the validity of this
study’s empirical results regarding FS effectiveness.
Our study is expected to make two contributions to
the literature. One is the validity of the IV method for
adjusting substantial self-selection inﬂuence in evalu-
ating FS effectiveness. BVP models and the example of
IVs employed in our analyses are expected to be useful
in evaluating other types of self-selected medical inter-
ventions where both an outcome and the intervention
are treated as dichotomous variables. Furthermore,
future studies are expected to control for additional
self-selection problems of pneumococcal vaccination
and smoking history through employing multivariate
probit models.
The second contribution is improved generalizabil-
ity in FS effectiveness based on the US nationally rep-
resentative study population. For instance, FS was
evaluated to be effective during the 1996–97 season
after controlling for nine census regions, although
these regions signiﬁcantly differed (P < 0.01) in key
individual factors such as FS rates, previous season’s
FS rates, penumococcal vaccination rates, chronic con-
dition levels and subjective general health status levels,
in addition to environmental factors like climate and
inﬂuenza epidemic levels. Future studies using addi-
tional inﬂuenza seasons are expected to improve the
generalizability of estimates of FS effectiveness even
further. Also, effectiveness evaluation studies focusing
on speciﬁc subpopulations at different levels of risks
could contribute to the appropriate allocation of vac-
cines to maximize the health beneﬁts of a vaccination
program particularly when vaccine supply is limited or
delayed as observed in the United States during 2004–
05 and recent inﬂuenza seasons [37,38].
Conclusion
Adjusting for self-selection, BVP analyses yielded vac-
cine effectiveness estimates for a nationally represent-
ative cross-sectional sample of the community-
dwelling elderly population that are consistent with
previous estimates based on randomized controlled tri-
als, prospective cohort studies, and meta-analyses.
This result suggests that IV methods in general and
analyses with 2SLS and BVP in particular may be use-
ful for the analysis of observational data regarding
prevention in which self-selection is an important
potential source of bias.
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